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Introduction
Breast cancer is the most common invasive 
malig  nancy among women in the United 
States, and the leading cause of death in 
women from their late 30s to early 50s (Brody 
et al. 2007b; Woloshin et al. 2008). The 
American Cancer Society (2010) estimated the 
global economic costs of pre  mature death and 
disability from breast cancer at $88 billion/year. 
Incidence rates vary dramatically over time 
and geogra  phy, with breast cancer rates higher 
in recent generations and in more-developed 
countries. Treatment is arduous, debilitating, 
and expensive, costing $17 billion/  year in 
the United States [Interagency Breast Cancer 
and Environment Research Coordinating 
Committee (IBCERCC) 2013]. Thus, the 
potential benefits of improving preventative 
efforts are large. Four authoritative panels have 
pointed to further study of environmental 
chemicals as a promising direction for preven-
tion [Cogliano et al. 2011; IBCERCC 2013; 
Institute of Medicine (IOM) 2011; President’s 
Cancer Panel 2010].
The rationale for studying environmental 
chemicals and breast cancer draws, in part, on 
epidemiological findings for other, easier to 
study, exposures. Preventable risk factors for 
breast cancer include medical radiation, aspects 
of reproductive history, increased body weight 
after menopause, lack of physical exercise, 
alcohol consumption, combination hormone 
replacement therapy (HRT), combination 
hormonal contraceptives, prenatal diethylstil-
bestrol (DES) exposure, and probably tobacco 
smoke [Hoover et al. 2011; IBCERCC 2013; 
International Agency for Research on Cancer 
(IARC) 2012; IOM 2011]. Several of these 
risk factors represent chemical exposures, 
suggesting that exposure to chemicals with 
similar properties may also pose preventable 
risks. For example, alcohol shares properties 
with other solvents, and tobacco smoke is but 
one member of a large family of toxicologi-
cally similar combustion products, including 
vehicle exhaust and air pollution. Given that 
pharmaceutical hormones are linked to breast 
cancer, other hormonally active chemicals 
likely also affect risk.
In addition, toxicological studies show 
genotoxicity, hormonal activity, and increased 
mammary tumors in rodents after exposure 
to many chemicals used in industry and 
consumer products and found in air and 
water, indicating that these and other chemi-
cals could affect breast cancer risk. We previ-
ously identified 216 chemicals that have been 
reported to increase mammary gland tumors 
in rodents (Rudel et al. 2007). Although the 
strength of the evidence linking these chemi-
cals to breast cancer varies, most of them also 
show evidence of genotoxicity and tumors at 
other sites, strengthening the case that they 
may also be carcinogenic in humans (Rudel 
et al. 2007). Many researchers have concluded 
that rodent mammary gland development and 
carcinogenesis is generally a good model for 
humans, as discussed in the well-developed 
literature on the subject (Cardiff et al. 2002; 
Russo IH and Russo J 1996; Russo J and 
Russo IH 1993, 2004) and as reflected in the 
consensus statements from a recent workshop 
that included > 50 academic and government 
scientists, including 26 whose research focus 
is on mammary gland biology and toxicology 
(Rudel et al. 2011). The IOM, the IARC, 
the IBCERCC, and others recommend using 
toxicological data, such as the mammary 
carcinogen list (Rudel et al. 2007), to set 
priorities for further research and possible 
exposure reduction (Cogliano et al. 2011; 
IBCERCC 2013; IOM 2011).
To implement these recommendations, 
researchers need tools to track human exposure. 
Exposure biomarkers—chemicals or metabo-
lites measured in biological media  —are prime 
tools because they can approximate internal 
dose and identify highly exposed groups. 
Alternative exposure assessment methods 
are limited: Self-reports are rarely useful for 
environ  mental chemicals because people are 
often unaware of their exposures. Women’s 
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Background: Exposure to chemicals that cause rodent mammary gland tumors is common, but 
few studies have evaluated potential breast cancer risks of these chemicals in humans.
oBjective: The goal of this review was to identify and bring together the needed tools to facilitate 
the measurement of biomarkers of exposure to potential breast carcinogens in breast cancer studies 
and biomonitoring.
Methods: We conducted a structured literature search to identify measurement methods 
for   exposure biomarkers for 102 chemicals that cause rodent mammary tumors. To evaluate 
concordance, we compared human and animal evidence for agents identified as plausibly linked to 
breast cancer in major reviews. To facilitate future application of exposure biomarkers, we compiled 
information about relevant cohort studies.
results: Exposure biomarkers have been developed for nearly three-quarters of these rodent 
mammary carcinogens. Analytical methods have been published for 73 of the chemicals. Some of 
the remaining chemicals could be measured using modified versions of existing methods for related 
chemicals. In humans, biomarkers of exposure have been measured for 62 chemicals, and for 45 
in a non  occupationally exposed population. The Centers for Disease Control and Prevention has 
measured 23 in the U.S. population. Seventy-five of the rodent mammary carcinogens fall into 
17 groups, based on exposure potential, carcinogenicity, and structural similarity. Carcinogenicity 
in humans and rodents is generally consistent, although comparisons are limited because few agents 
have been studied in humans. We identified 44 cohort studies, with a total of > 3.5 million women 
enrolled, that have recorded breast cancer incidence and stored biological samples.
conclusions: Exposure measurement methods and cohort study resources are available to expand 
biomonitoring and epidemiology related to breast cancer etiology and prevention.
citation: Rudel RA, Ackerman JM, Attfield KR, Brody JG. 2014. New exposure biomarkers as 
tools for breast cancer epidemiology, biomonitoring, and prevention: a systematic approach based on 
animal evidence. Environ Health Perspect 122:881–895;  http://dx.doi.org/10.1289/ehp.1307455Rudel et al.
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work histories have not lent themselves to occu-
pational assessments for breast cancer, although 
this is changing, and geographic location can be 
useful only in limited situations involving acci-
dents or disasters or when environmental moni-
toring data are available. In addition to their use 
in epidemiological studies, exposure biomarkers 
are valuable for tracking exposure levels in 
the general popula  tion [e.g., via the National 
Health and Nutrition Examination Survey 
(NHANES) and in subgroups with unusual 
exposures or vulnerabilities] and for designing 
and assessing exposure reduction efforts.
Despite its potential power, the use of 
exposure biomarkers in breast cancer research 
has so far been limited to a few types of 
chemicals. This review was intended to expand 
epidemiology studying breast cancer and 
environment by bringing together needed 
tools. Our previous work used toxicological 
studies to identify priority chemicals for breast 
cancer studies based on biological plausibility 
(Rudel et al. 2007, 2011). The information we 
present here builds on that work by describing 
methods available for exposure assessments 
in epidemiological studies. Because reducing 
exposure to plausible breast carcinogens can 
help prevent breast cancer, we also highlight 
new priorities for biomonitoring programs 
to effectively monitor population exposure, 
identify highly exposed groups, and evaluate 
exposure reduction efforts.
To expand the use of exposure biomarkers 
relevant to breast cancer, we summarized 
biomonitoring measurement methods for 
chemicals that cause mammary gland tumors 
in animals. We focused on 102 chemi-
cals to which large numbers of women are 
likely exposed. To inform the use of these 
biomarkers, we also summarized exposure 
levels in NHANES and in special populations 
and identified common exposure sources. We 
prioritized the chemicals and grouped them 
based on exposure, carcinogenic potential, 
and chemical structure. To facilitate discus-
sion of the breast cancer relevance of rodent 
mammary gland carcinogens, we compared 
relevant human and animal evidence, and we 
discuss the strengths and limitations of this 
inference. Finally, we compiled a list of cohort 
studies with stored biological samples in which 
exposure biomarkers could readily be applied.
Methods
Chemical selection. We previously identified 
216 chemicals as potential breast carcinogens 
because they caused mammary gland tumors 
in rodent studies (Rudel et al. 2007), based 
on information from Gold et al. (2005), the 
National Toxicology Program (NTP 2005a, 
2005b), IARC Monographs published in 
or before 2005 (Volumes 1–85; http:// 
monographs.iarc.fr/ENG/Monographs/PDFs/), 
and the Chemical Carcinogenesis Research 
Information System (CCRIS; http://toxnet.
nlm.nih.gov/newtoxnet/ccris.htm). We then 
identified 102 of these 216 as having broad 
exposure in the population because a) they are 
produced in high volumes (Rudel et al. 2007); 
b) > 5,000 women are occupationally exposed 
each year (Rudel et al. 2007); c) they are present 
in food, air pollution, or consumer products 
(Rudel et al. 2007); d) they are pharmaceuticals 
that have been prescribed to large numbers of 
women (Friedman et al. 2009); or e) they are 
pharmaceuticals often prescribed to pregnant 
women (Hoover et al. 2011).
Systematic search and summary of 
exposure biomarkers. We searched PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) 
to identify exposure biomarkers for the 
102 selected chemicals. For each chemical, 
we searched for studies using a biomarker 
of exposure on occupationally or environ-
mentally exposed populations or the general 
population, as well as recent (since 2000) 
studies of biomarker method development, 
which might use small numbers of human 
or animal samples. We excluded studies of 
metabolism and distribution, methods in 
environmental media (e.g., air, water, soil, 
dust), and biomarkers of early effect (e.g., 
oxidative stress, apoptosis) unless the effect 
was specific to that chemical. The search 
format was as follows: {(chemical name) OR 
[Chemical Abstracts Service number (CAS)]} 
AND (biomarker OR biological marker OR 
biological monitoring OR urine OR blood).
When the initial search returned > 400 
results, we refined the search by adding 
keywords, depending on the nature of the 
irrele  vant results. Additional keywords 
included “exposure” or “(chromatography 
OR spectrometry OR assay OR detection OR 
quantification OR quantitation)” or “(occu-
pational OR population OR human).” If the 
initial search returned < 10 results, we also 
searched for ([chemical name] OR [CAS]) 
AND (chromatography OR spectrometry 
OR assay OR detection OR quantification 
OR quantitation). When the initial search 
returned no useful results, we also searched 
for “[chemical name] OR [CAS],” which in a 
few cases yielded relevant results that had not 
appeared in the initial search.
We reviewed NHANES reports, informa-
tion on the Centers for Disease Control and 
Prevention (CDC) website (CDC 2014), and 
articles with information about NHANES 
results and methods in order to identify 
NHANES analytical methods currently used 
to measure exposure to the 102 mammary 
carcinogens of interest, as well as to identify 
methods that could easily be adapted to do so.
We then reviewed and summarized the 
abstracts, reports, and review articles retrieved 
by these searches. In preparing the summaries, 
we gave more careful attention to review articles 
(which we retrieved and read in their entirety), 
to more recent articles (since 2005, or since 
2000 for chemicals that had fewer results), and 
to those that included information on analytical 
methods in the abstract. In a few cases, we 
included additional information from modified 
searches. The summaries followed a standard 
format that included the most sensitive method 
or methods found a) for each biological 
medium (primarily blood and urine); b) for the 
parent compound, metabolites, and adducts; 
and c) for general population and occupational 
settings. Although we searched for methods 
only for blood and urine, we included methods 
in other media (e.g., saliva, breast milk) if these 
appeared in the search results. We included 
quantification limits and concentrations 
reported in human populations.
Anticipated sources of exposure. We 
previously (Rudel et al. 2007) reported infor-
mation on anticipated sources of exposure 
from Budavari et al. (1996), Department of 
Health and Human Services (DHHS 2004), 
Environmental Defense Fund (2004), Food 
and Drug Administration (2005), IARC 
(http:// monographs.iarc.fr/ENG/Monographs/
PDFs/), National Institute for Occupational 
Safety and Health 1990, NTP (2005a, 
2005b), Pesticide Action Network (2000), 
U.S. Environmental Protection Agency (U.S. 
EPA 2005a, 2005b), and toxicological data-
bases [CCRIS (Household Products Database; 
http://hpd.nlm.nih.gov/), HSDB (Hazardous 
Substances Data Bank; http://toxnet.nlm.nih.
gov/newtoxnet/hsdb.htm), PubChem (http://
pubchem.ncbi.nlm.nih.gov/), and Toxnet 
(Toxicology Data Network; http://toxnet.nlm.
nih.gov/)]. In the present work, we added infor-
mation from the Canadian Priority Substances 
List (Health Canada 2001), California 
Proposition 65 listings [California Office of 
Environmental Health Hazard Assessment 
(California OEHHA) 2014], the NTP 12th 
Report on Carcinogens (NTP 2011), U.S. EPA 
Action Plans (U.S. EPA 2012), and European 
Chemicals Agency (ECHA) listings of 
substances of very high concern (ECHA 2013).
U.S. population levels reported in the 
CDC exposure report. Of the chemicals in our 
list, 23 are, have been, or will be included in 
NHANES (CDC 2009) as are a number of 
polycyclic aromatic hydro  carbons (PAHs) that 
may serve as reasonable proxies for exposure to 
the carcinogenic PAHs on our list. For these, 
we reviewed full papers and identified analy-
tical methods for blood and urine, detection 
limits, and detection frequencies in NHANES 
analyses of the general population.
Priorities for breast cancer–relevant 
epidemiology and biomonitoring. We identi-
fied priority chemicals or chemical families 
based on exposure and carcinogenicity 
and then condensed the chemical list by 
combining chemicals with similar structures Exposure biomarkers for breast cancer epidemiology
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and measurement methods (e.g., nitro-PAHs, 
heterocyclic amines). We prioritized chemi-
cals by whether we anticipated widespread 
exposure, there was suggestive evidence of 
breast cancer risk in epidemiological studies, 
or they were   prioritized for attention by 
 governmental  agencies.
Animal–human concordance for breast 
cancer. To evaluate the strength of evidence 
supporting an inference that rodent mammary 
carcinogens are also likely to be human breast 
carcinogens, we compared human and animal 
evidence for agents identified as plausibly 
linked to breast cancer in major reviews. We 
based our assessments of human evidence on 
IARC assessments for nine agents (Cogliano 
et al. 2011; IARC 2012). For human evidence 
on hetero  cyclic amines and four organo-
chlorines, we relied on other authoritative 
reviews (Brody et al. 2007b; Hoover et al. 
2011; Michels et al. 2007), and for five 
non  hormonal pharmaceuticals, we relied on 
an observational study from Kaiser Permanente 
(Friedman et al. 2009). Animal study findings 
came from original research papers, NTP 
reports, and other government reports.
Cohort studies. We compiled a list of 
cohort studies that have collected biological 
samples and health data from women, so 
researchers can readily find opportunities to 
apply the exposure biomarkers prospectively. 
We identified studies by searching the 
National Institutes of Health (NIH) 2009 
Computer Retrieval of Information on 
Scientific Projects (CRISP) (NIH 2009) and 
2012 RePORTER (NIH 2012) databases 
with the terms “breast cancer cohort,” exam-
ining other online resources (Environmental 
Health Risk in European Birth Cohorts 
2010; National Cancer Institute 2013, 2014), 
communicating with researchers studying 
women’s health, and examining articles 
listed in PubMed as “related” to those from 
studies previously identified. For each cohort, 
we collected the following information: 
institution(s), principal investigator(s), funder, 
study population, study period, exposure 
measurements, health outcomes, and study 
website. We verified the information with the 
study investigators or contact people   identified 
on study websites.
Results
We identified exposure-source information 
for all 102 of the rodent mammary carcino-
gens and exposure biomarker methods for 73. 
The CDC has measured or will soon measure 
biomarkers of exposure to 23 of these in the 
general U.S. population. We found 19 agents 
with evidence as human breast carcinogens 
that could be compared for concordance 
with animal studies. We identified 60 cohort 
studies, covering > 3.5 million women and 
girls, that have collected biological samples 
in which these biomarkers could be tested 
and evaluated in relation to breast cancer or 
pubertal development.
Exposure biomarker methods. We 
found exposure measurement methods for 
almost three-quarters of the 102 mammary 
carcinogens. Specifically, methods have 
been published for 73 of the chemicals, and 
biomarkers for 62 have been measured in 
humans, 45 of these in a non  occupationally 
exposed population. Exposure to 23 (plus 
non  carcinogenic PAHs) has been or will soon 
be measured through validated methods in 
the NHANES study of the U.S. population 
(see Supplemental Material, Table S1). Some 
of the chemicals for which we did not find 
methods could be analyzed using existing 
methods for structurally related compounds.
Generally, the biomarker methods 
measure either the parent compound in blood 
or a metabolite—sometimes not specific to a 
single parent compound—in urine. DNA and 
protein adducts, consisting of the parent or 
metabolite bound to DNA or to a protein, are 
also widely used. In this review, metabolites 
are considered to be specific to the parent 
compound unless noted otherwise.
Measurements in the NHANES sample 
of the U.S. population (Table 1) show 
Table 1. Rodent mammary gland carcinogens included in NHANES exposure surveillance.
Parent chemical Blood biomarker Urine biomarker Detection frequency (%) Reference
1,1-Dichloroethane 1,1-Dichloroethane None < 5 CDC 2009
1,2-Dibromo-3-chloropropane 1,2-Dibromo-3-chloropropane None < 5 CDC 2009
1,2-Dibromoethane None HEMA (nonspecific)a 71 (nonspecific metabolite)a Alwis et al. 2012; Calafat et al. 1999
1,2-Dichloroethane 1,2-Dichloroethane None < 5 CDC 2009
1,2-Dichloropropane 1,2-Dichloropropane None < 5 CDC 2009
1,3-Butadiene None MA metabolites NA Alwis et al. 2012
Acrylamide Hb adducts of acrylamide and 
glycidamide
MA metabolites > 50 (blood) Alwis et al. 2012
Acrylonitrile None HEMA (nonspecific)a; specific MA 
metabolite
71 (nonspecific metabolite)a Alwis et al. 2012; Calafat et al. 1999
Atrazine None Atrazine mercapturate < 5 CDC 2009
Benzene Benzene MA metabolites > 50 (blood) Alwis et al. 2012; CDC 2009
Carbon tetrachloride Carbon tetrachloride None < 5, 2003–2004 (> 25, 2001–2002) CDC 2009
Chlordane Serum: oxychlordane,  
trans-nonachlor
None > 50 CDC 2009
Dichlorvos None Dimethyl phosphate (nonspecific)b > 25 (nonspecific metabolite)b CDC 2009
Ethylene oxide Hb adducts HEMA (nonspecific)a 71 (nonspecific urinary  
metabolite)a
Alwis et al. 2012; Calafat et al. 
1999; CDC 2008
Propylene oxide Hb adducts MA metabolites NA Alwis et al. 2012; CDC 2008
Fenvalerate None Phenoxybenzoic acid (nonspecific)c 75 (nonspecific metabolite)c CDC 2009; Riederer et al. 2008
Methylene chloride Methylene chloride None < 5 CDC 2009
Methyleugenol Serum: methyleugenol None 98 Barr et al. 2000
Nitrobenzene Nitrobenzene None < 5 CDC 2009
PAHsd None 22 metabolites (e.g.,  
1-hydroxypyrene)
98 CDC 2012; Li et al. 2008
PFOA Serum: PFOA None > 50 CDC 2012
Styrene Styrene MA metabolite, mandelic acid > 25 (blood) Alwis et al. 2012; CDC 2009
Vinyl chloride None HEMA (nonspecific)a 71 (nonspecific metabolite)a Alwis et al. 2012; Calafat et al. 1999
Vinylidene chloride 
(1,1-dichloroethene)
Vinylidene chloride None < 5 CDC 2009
Abbreviations: Hb, hemoglobin; HEMA, 2-hydroxyethyl mercapturic acid; MA, muconic acid; NA, not applicable; PFOA, perfluorooctanoic acid.
aA metabolite of vinyl chloride, ethylene oxide, 1,2-dibromoethane, acrylonitrile, and other electrophilic two-carbon compounds (Alwis et al. 2012; Calafat et al. 1999).   bA metabolite of 
> 15 organophosphate insecticides, including dichlorvos, malathion, and methyl parathion (CDC 2009). cA metabolite of ≥ 6 pyrethroid insecticides (CDC 2009). dPAH metabolites have 
not been identified as rodent mammary carcinogens in this method, but exposure is likely to be correlated with carcinogenic PAHs or nitro-PAHs, in some cases.Rudel et al.
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that some biomarkers are detected in most 
people, whereas others are rarely detected, 
although exposures may be more common in 
subpopulations. The CDC National Center 
for Environmental Health laboratory that 
performs these measurements often collabo-
rates with epidemiologists to analyze biolog-
ical samples in their studies.
Supplemental Material, Table S1, summa-
rizes known sources of exposure and methods 
for biomonitoring for each of the 102 rodent 
mammary gland carcinogens. These 102 
carcinogens comprise a diverse set of chemi-
cals and exposures, including components of 
automobile exhaust, gasoline, and air pollu-
tion (1,3-butadiene, benzene, PAHs, nitro-
PAHs), chemicals in food and drinking 
water [acrylamide, ochratoxin A, heterocyclic 
amines, styrene, 3-chloro-4-(dichloromethyl)-
5-hydroxy-2(5H)-furanone (MX)], chemicals 
in consumer products and building materials 
(flame retardants, aromatic amines, perfluo-
rinated compounds), pharmaceuticals, and 
endocrine disruptors as well as some chemicals 
with important occupational exposures [halo-
genated solvents, ethylene oxide (EtO)]. From 
this list, we identified higher-priority chemi-
cals or chemical families based on exposure 
and carcinogenicity, as indicated below, 
resulting in 17 chemicals or groups of related 
chemicals. We prioritized chemicals/  chemical 
groups based on stronger, more consistent 
mammary tumor effects in animal studies, 
greater exposure potential, and availability of 
methods. Exposure sources and measurement 
methods for these 17 chemicals and chemical 
groups are summarized in Table 2, and each 
is discussed briefly below. The groups may 
contain some individual chemicals that are not 
high priority on their own but which can be 
measured by the same method as a prioritized 
chemical. Conversely, the 27 chemicals not 
Table 2. Priority chemicals for breast cancer–relevant epidemiology and biomonitoring.
Chemical Common exposure sources Biomarkers
1,3-Butadiene Gasoline, vehicle exhaust, tobacco smoke, heating of some 
cooking oils
DNA and hemoglobin adducts in blood, derived from epoxide 
metabolites; mercapturic acid metabolites in urine
Acrylamide Cooked food, tobacco smoke, water-treatment by-products, 
some consumer products
Hemoglobin adducts of acrylamide and glycidamide in blood; urinary 
mercapturic acid metabolites of acrylamide and glycidamide
Aromatic amines I: TDA and TDIs Uncured or newly finished polyurethane foam, spray-in 
insulation, sealants and coatings, some breast implants
TDA and hemoglobin adducts in blood, TDA in urine 
(Most studies have tested occupationally exposed populations, but 
many find TDA in “unexposed” controls)
Aromatic amines II: benzidine and aniline 
dyes, combustion products, other
Hair and textile dyes; used in the production of paints, 
printing inks, liquid crystal displays, and inkjet and laser 
printers, and in the food industry
Parent compound in blood or urine; DNA and hemoglobin adducts in 
blood or breast milk
Benzene Gasoline, vehicle exhaust, tobacco smoke, solvents DNA and protein adducts in blood and dried blood spots; urinary 
metabolites sPMA (specific to benzene) and ttMA (metabolite of 
benzene and the common food preservative sorbate)
Halogenated organic solvents (e.g., 
methylene chloride)
Dry cleaning, spot remover, glues, degreasers, paint 
strippers, aerosol propellants, contaminated drinking water
(Use is decreasing over time)
Parent compound in whole blood and urine 
Infrequently detected in blood from general population but widespread 
occupational exposure has been documented; parent compounds 
have been detected in urine from occupationally exposed populations, 
and methylene chloride has been detected in urine from general 
population
Ethylene oxide, propylene oxide Tobacco smoke, food and medical sterilization, vehicle 
exhaust, paint
DNA and hemoglobin adducts in blood; mercapturic acid metabolites 
in urine
Flame retardants and degradation 
products [2,2-bis(bromomethyl)-1,3-
propanediol, 2,3-dibromo-1-propanol]
Flame retardants; primarily used in plastics and foams Parent compound or metabolite in urine
Heterocyclic amines Grilled meat Parent compound, protein adducts, and DNA adducts in blood; parent 
compound in urine and hair
Hormones and endocrine disruptors 
(e.g., endogenous and exogenous 
estrogens and estrogen mimics)
Pharmaceutical hormones, consumer products, and 
commercial chemicals with hormonal activity
Clinical and research methods are available to measure endogenous 
hormone levels in blood and urine; the MCF-7 cell proliferation 
assay has been used to measure estrogenic activity in extracts of 
adipose tissue from breast cancer cases and controls; development 
of methods to conduct this assay in blood, and to distinguish 
endogenous and exogenous estrogen signals, would allow integrated 
assessments of exposure to xenoestrogens
MX Water disinfection Urinary trihaloacetic acids are used as exposure biomarkers for 
chlorinated drinking water, but improved exposure biomarkers are 
needed for MX and other highly genotoxic disinfection by-products
Nitro-PAHs (e.g., 1-nitropyrene) Diesel exhaust Hemoglobin adducts in blood, metabolites in urine
Ochratoxin A Mycotoxin in grains, nuts, pork; also present in moldy 
environments
Ochratoxin A and its metabolites in blood, urine, breast milk
PAHs (e.g., BaP) Vehicle exhaust, tobacco smoke, charred food Protein adducts and DNA adducts in blood; oxidized metabolites in 
urine; parent compounds measured in hair, breast milk 
(Improved exposure biomarkers are needed)
PFOA, related compounds Grease-, water-, and stainproof coatings; contaminated 
drinking water
Parent compound in blood and breast milk
Pharmaceuticals  (non hormonal) A number of over-the-counter, veterinary, and prescription 
medicines that induce mammary tumors
Few exposure biomarkers have been developed for use in the general 
population, but in many cases LC-MS/MS methods have been 
reported for the parent compound in plasma or metabolites in urine; in 
some cases exposure can be ascertained from self-report or medical 
records
Styrene Building materials and consumer products made from 
polystyrene; indoor air, cigarette smoke, polystyrene food 
packaging
Parent compound in whole blood; urinary mercapturic and mandelic 
acid metabolites
Abbreviations: BaP, benzo[a]pyrene; LC-MS/MS, liquid chromatography–tandem mass spectrometry; PFOA, perfluorooctanoic acid; sPMA, S-phenylmercapturic acid; TDA, 2,4-toluene 
diamine; TDI, toluene diisocyanates; ttMA, trans, trans-muconic acid. For more information, including a list of chemicals in each group, see Supplemental Material, Table S1.Exposure biomarkers for breast cancer epidemiology
Environmental Health Perspectives  •  volume 122 | number 9 | September 2014  885
part of the 17 groups are still of high interest 
for breast cancer studies, and some of them 
can be measured with—or could be incor-
porated into—existing methods. Chemical 
structures for all the chemicals along with 
additional information on regulation, govern-
mental assessments, exposure, and health 
effects are collected in the Silent Spring 
Institute Mammary Carcinogens Review 
Database (http://sciencereview.silentspring.
org/mamm_about.cfm).
1,3-Butadiene. 1,3-Butadiene exposure in 
the general population is primarily via inhala-
tion of cigarette smoke, automobile exhaust, 
and gasoline fumes as well as via emissions 
from industrial facilities. Occupational 
exposure occurs in many industries, espe-
cially synthetic rubber manufacturing and 
petroleum refining, with > 12 billion pounds 
per year produced globally (Occupational 
Safety and Health Administration 2012). 
Many occupational studies, epidemiological 
studies, and studies comparing smokers 
and non  smokers have used biomarkers of 
exposure to 1,3-butadiene in blood and urine. 
Common approaches include measuring 
DNA and hemoglobin adducts in blood 
(Il’yasova et al. 2009; Ogawa et al. 2006; 
Swenberg et al. 2011) and measuring mercap-
turic acid metabolites in urine (Alwis et al. 
2012). The CDC is planning to measure the 
urinary mercapturic acid metabolites in future 
NHANES reports (Alwis et al. 2012). DNA 
and hemoglobin adducts are likely to repre-
sent cumulative exposure over several weeks 
or longer, whereas urinary metabolite levels 
reflect more recent exposures (Boogaard 2002; 
Carmella et al. 2009).
Acrylamide. Major sources of acrylamide 
exposure include diet (especially starchy 
foods cooked at high temperatures such as 
french fries) and tobacco smoke. Acrylamide 
exposures are believed to be low from other 
sources such as grouts, adhesives, and poly-
acrylamide gels used in many consumer 
products (e.g., diapers) and in drinking-water 
treatment. The CDC has measured the hemo-
globin adducts of acrylamide and its metabo-
lite glycidamide (CDC 2009) and plans to 
measure urinary mercapturic acid metabolites 
of acrylamide and glycidamide in NHANES 
participants (Alwis et al. 2012).
Aromatic amines. Aromatic amines 
contain nitrogen bound to benzene or other 
aromatic rings. They are important inter-
mediates in the industrial synthesis of poly-
urethane, pesticides, dyes, and many other 
products. We identified 15 aromatic amines 
that produce mammary gland tumors in 
rodent cancer bioassays (see Supplemental 
Material, Table S1). Many other commer-
cially important aromatic amines have not 
been tested for carcinogenicity in rodents. 
The 15 that caused rodent mammary tumors 
comprise 2,4-toluene diamine (TDA) and 
toluene diisocyanate (TDI), and 13 associ-
ated with azo dyes and combustion sources. 
Methods for biomonitoring them typically 
involve measuring the parent compound 
in blood or urine, or DNA or hemoglobin 
adducts of the parent compound (see 
Supplemental Material, Table S1).
TDA is an aromatic amine metabo-
lite of TDI, which is used in the produc-
tion of polyurethane foams and sealants. 
The U.S. EPA recently created an action 
plan for TDI because of the potential for 
exposure from spray-in foam insulation and 
sealants containing TDI (U.S. EPA 2011b). 
In addition to concerns about cancer, TDI 
exposure has been shown to cause asthma and 
lung damage (U.S. EPA 2011b). Exposures 
to trinitrotoluene and dinitrotoluene, used 
in explosives and munitions, also produce 
elevated levels of TDA in urine and blood 
(ECHA 2013). Exposure to TDA is usually 
assessed by measuring the chemical in urine 
or blood samples, and some studies have 
measured hemoglobin adducts of TDA (Jones 
et al. 2005). A study of women with poly-
urethane breast implants detected TDA in 
the urine of about half the study participants 
(Hester et al. 1997).
Azo dyes are derivatives of aromatic amines 
such as benzidine and aniline. Most of these 
are no longer used or produced in the United 
States, Europe, or Japan—in part because they 
are known to cause bladder cancer in humans 
(NTP 2011). However, many azo dyes are 
still produced and used in significant quan-
tities, mostly in Asia (U.S. EPA 2010), in 
the production of textiles, hair dyes, paints, 
printing inks, paper, and pharma  ceuticals; as 
reagents and biological stains in laboratories; 
in the food industries; and in liquid crystal 
displays, laser and inkjet printers, and electro-
optical devices (U.S. EPA 2010). One study 
reported DNA–aminobiphenyl adducts in 
epithelial-cell DNA isolated from human 
breast milk in women who had used hair-
coloring products (Ambrosone et al. 2007).
Some aromatic amines (e.g., 4-amino-
biphenyl) are present in tobacco smoke and 
other combustion products (NTP 2011).
Benzene. The highest exposures to 
benzene are from gasoline (from, e.g., riding 
in a car, pumping gasoline, storing gasoline 
in a basement or attached garage) and 
tobacco smoke, although automobile exhaust 
and other forms of urban and industrial air 
pollution are also important exposure sources 
(Dodson et al. 2007; NTP 2011). Benzene 
is also used in some consumer products, 
including adhesive removers, paints, sealants, 
finishers, and engine fuel and oils (DHHS 
2004). The CDC and others have measured 
benzene in blood samples taken from the 
general population, generally detecting it in 
all or most samples; however, this method 
requires a relatively large (3–10 mL) whole 
blood sample and only reflects recent 
exposure (Blount et al. 2006). Others have 
measured benzene in urine and breath, 
benzene metabolites in urine, and adducts to 
proteins and DNA in blood and dried blood 
spots (see Supplemental Material, Table S1). 
At present, the CDC plans to perform 
benzene biomonitoring in NHANES by 
measuring urinary mercapturic acid metabo-
lites (Alwis et al. 2012).
Halogenated organic solvents. We identi-
fied methylene chloride and nine other organic 
solvents as causing mammary gland tumors 
in animal bioassays. These chemicals were 
widely used in the past, with uses including 
dry cleaning, hair-spray propellant, soil fumi-
gants, food processing, gasoline additives, 
and paint and spot removers. Although their 
use has declined, occupational exposures are 
still common, and some consumer exposure 
remains. In past years, the CDC has measured 
blood levels of some of these chemicals in 
NHANES, but the method requires a relatively 
large (3–10 mL) whole blood sample, only 
reflects recent exposure, and is vulnerable to 
contamination by laboratory solvents (Blount 
et al. 2006) (see Supplemental Material, 
Table S1). Methods may be developed to 
measure parent compounds or metabolites 
of halogenated organic solvents in urine, but 
these will likely still reflect only recent expo-
sures and be vulnerable to contamination. The 
CDC plans to measure urinary mercapturic 
acid metabolites of many volatile organic 
compounds (VOCs) in NHANES samples, 
and possibly some of these halogenated VOCs 
could be integrated into this method (Alwis 
et al. 2012) although the only metabolite of 
a halogenated mammary carcinogen to be 
measured by this method is 2-hydroxyethyl 
mercapturic acid (HEMA), a common metabo-
lite of 1,2-dibromoethane, vinyl chloride, 
acrylonitrile, and EtO (Calafat et al. 1999; 
CDC 2009). Other potential non  specific 
biomarkers include haloacetic acids and 
  haloalcohols in urine.
EtO and 1,2-propylene oxide (PO). 
EtO is a gas used to sterilize medical equip-
ment, food and spices, clothing, and musical 
instruments (NTP 2011). It has also been 
detected in tobacco smoke and auto exhaust 
(NTP 2011). EtO is a high-production-
volume chemical used to manufacture many 
other chemicals such as ethylene glycol; thus, 
one exposure source might be air pollu-
tion near industrial facilities (NTP 2011). 
Occupational exposure has been wide-
spread, including in health care settings, but 
exposure levels have been decreasing with 
time (NTP 2011). The CDC has measured 
the non  specific urinary metabolite HEMA 
(Calafat et al. 1999; CDC 2009) and plans to Rudel et al.
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add EtO-hemoglobin adducts to the current 
method that measures acrylamide- and 
glycidamide-derived hemoglobin adducts in 
NHANES blood samples (CDC 2008). DNA 
adducts of EtO have been measured in occu-
pational and general population studies (e.g., 
Czene et al. 2002; Schettgen et al. 2010). 
Urine measurements reflect recent exposures, 
whereas DNA or protein adducts reflect 
cumulative exposure over weeks or months.
PO, another high-production-volume 
industrial chemical, is used to manufacture 
other chemicals (including polyurethane 
foam) and as a sterilant and fumigant and is 
used in some automotive and paint products 
(NTP 2011). Tobacco smoke is also a source 
of exposure (IARC 2010). The CDC plans to 
measure a PO-derived mercapturic acid in the 
urine of NHANES participants (Alwis et al. 
2012). Hemoglobin and DNA adducts have 
also been used to measure exposures in some 
studies, and the CDC method for measuring 
acrylamide-derived hemoglobin adducts in 
blood was first developed to measure PO 
exposure (CDC 2008).
Flame retardants and metabolites. 
We identified a flame retardant and a flame 
retardant metabolite, with similar chemical 
structures, that are genotoxic and also potent 
multisite carcinogens, including in the 
mammary gland. 2,2-Bis(bromomethyl)-1,3-
propanediol is a high-production-volume 
flame retardant used in polyester resins, plastic 
polymers, and rigid polyurethane foams (NTP 
2011). It is expected to be very persistent in 
water; however, it is rapidly glucuronidated 
and excreted by rats, and less rapidly excreted 
by humans (Hoehle et al. 2009; Kong et al. 
2011; Rad et al. 2010). The second chemical 
of interest is 2,3-dibromo-1-propanol, which 
is an impurity, degradation product, and 
metabolite of two flame retardants: tris(2,3-
dibromopropyl) phosphate, formerly used in 
children’s pajamas before this use was restricted 
in 1977, and tetrabromo  bisphenol A bis 
(2,3-dibromopropyl ether), a high-production-
volume chemical currently used in plastics 
(NTP 2002). Several flame retardants with 
similar or identical structures except for the 
substitution of chlorine for bromine atoms 
[e.g., tris (dichloropropyl) phosphate, also 
known as chlorinated tris] also seem likely 
to increase breast cancer risk. Although these 
chlorinated tris alkyl phosphates are known 
carcinogens (California OEHHA 2014), 
to our knowledge rodent studies have not 
reported mammary tumors.
Biomarkers for these halogenated tris-
alkylphosphate flame retardants and their 
degradation products are not well developed. 
2,3-Dibromo-1-propanol has been measured in 
urine by gas chromatography–mass spectrom-
etry (GC-MS) (Blum et al. 1978; De Alwis 
et al. 2007) and bis(1,3-dichloro-2-propyl) 
phosphate, a metabolite of chlorinated 
tris, has been analyzed in urine by liquid 
  chromatography–tandem mass spectrometry 
(LC-MS/MS) (Cooper et al. 2011). Knowledge 
gaps include pharmacokinetic studies to 
identify suitable metabolites for biomonitoring 
and methods development, including synthesis 
of analytical standards.
Heterocyclic amines. Both meat cooked 
at high temperatures and tobacco smoke 
contain heterocyclic amines (NTP 2011), 
four of which have been associated with 
mammary gland tumors in rodents. Although 
biomarkers of exposure have been developed 
and used in epidemiological studies of cancer 
risk, including for breast cancer, most epide-
miological studies have used self-reported 
dietary intake and smoking as exposure 
measures. Common exposure biomarkers are 
protein or DNA adducts in blood or tissues, 
the parent compound in blood or hair, and 
the parent compound or metabolites in urine 
(see Supplemental Material, Table S1).
Endogenous and pharmaceutical 
hormones and other endocrine-disrupting 
chemicals (EDCs). Estrogens, progesterone, 
and DES—along with other hormones—cause 
mammary gland tumors in rodents, and a few 
weaker EDCs have shown modest mammary 
tumor effects in rodent bioassays (e.g., amsonic 
acid, which is used in the manufacture of 
fluorescent whitening agents) (Rudel et al. 
2007). EDCs may also affect breast cancer 
risk via pathways that would not be evident 
in rodent cancer screens, for example, by 
altering mammary gland development (Rudel 
et al. 2011). Clinical laboratories commonly 
measure estradiol and other steroid hormone 
levels in blood by immunoassay, although such 
methods are imprecise and prone to inter-
ference from other hormones and hormone-
binding proteins in serum or plasma (Blair 
2010; Cao et al. 2004; Rosner et al. 2013). 
GC-MS and LC-MS/MS methods in blood 
and urine are more precise, sensitive, and 
specific (Blair 2010; Rosner et al. 2013; 
Stanczyk and Clarke 2010).
Chemicals known to be EDCs can be 
individually quantified. In addition, theo-
retically, functional tests can give estimates of 
total exposure to estrogenic activity or other 
forms of endocrine disruption; however, these 
methods are not yet well developed for use in 
biological samples. The MCF-7 cell prolifera-
tion assay has been used to measure estro-
genic activity in extracts of adipose tissue in 
breast cancer cases and controls (Fernandez 
et al. 2007). The development of methods to 
conduct this assay in blood, and to distinguish 
endogenous and exogenous estrogen signals, 
would allow integrated assessments of exposure 
to xenoestrogens. In addition, functional assays 
in biological samples to measure EDC activity 
affecting non  estrogenic pathways would 
allow epidemiologists to study the impact 
of other hormonal   mechanisms on breast 
carcinogenesis.
MX. MX is one of hundreds of genotoxic 
by-products of drinking-water disinfection. 
Although MX concentrations are typically 
much lower than those of regulated disin-
fection by-products, MX is more potently 
genotoxic and carcinogenic (McDonald 
and Komulainen 2005; Richardson et al. 
2007). Exposure biomarkers are needed for 
MX and related disinfection by-products 
(Savitz 2012). A number of epidemiological 
studies of drinking-water disinfection expo-
sures use urinary trihaloacetic acids, which 
are metabolites of other common disinfec-
tion by-  products, as exposure biomarkers 
(Savitz 2012; Weisel et al. 1999). It is not 
known whether they are good proxies for the 
  mutagenic disinfection by-products.
Nitro-PAHs. 1-Nitropyrene and other 
nitroPAHs are air pollutants thought to 
primarily come from diesel exhaust. Few 
studies have characterized general-population 
exposure levels, but biomarkers of exposure 
include urinary metabolites (e.g., 1-amino-
pyrene) (Huyck et al. 2010; Laumbach 
et al. 2009; Toriba et al. 2007) and hemo-
globin adducts in blood (Zwirner-Baier and 
Neumann 1999). Six of these compounds—
1,3-dinitro pyrene,  1,8-dinitro pyrene,  1-nitro-
pyrene, 2-nitrofluorene, 4-nitropyrene, 
6-nitrochrysene—are especially potent rodent 
mammary gland carcinogens (Rudel et al. 
2007), making the development of better 
exposure biomarkers a high priority.
Ochratoxin A. Human exposure to the 
naturally occurring mycotoxin ochratoxin A 
occurs mainly through the consumption of 
contaminated grain, nuts, and pork products 
(IARC 1993; NTP 2011). Ochratoxin 
contami  nation of crops is more prevalent in 
some regions (e.g., the Balkan countries). 
Exposure has also been reported in individ-
uals in the United States exposed to mold-
contaminated environ  ments (Hooper et al. 
2009). Exposure biomarkers include measure-
ment of the parent compound in blood, 
urine, breast milk, and other tissues using 
immunoassay methods with   fluorescence 
detection as well as LC-MS/MS approaches 
(Hooper et al. 2009; Scott 2005). In a 
pilot study, Muñoz et al. (2009) suggested 
that levels of metabolites may be much 
higher than those of the parent compound 
in blood and urine and thus may be better 
exposure biomarkers.
PAHs. Exposure to PAHs, such as 
benzo[a]pyrene (BaP), occurs primarily 
through inhalation of tobacco smoke or 
polluted air and the ingestion of charred 
foods (NTP 2011). Of the five PAHs 
shown to cause mammary gland tumors in 
rodents, two—3-methylcholanthrene and Exposure biomarkers for breast cancer epidemiology
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7,12-dimethylbenz[a]anthracene—are 
primarily used in research laboratories and 
three—BaP, dibenz[a,h]anthracene, and 
dibenzo[def,p]chrysene—are commonly 
measured products of combustion (see 
Supplemental Material, Table S1). However, 
air pollution and other combustion products 
are complex mixtures of many PAHs, most 
of which have not been evaluated for carcino-
genicity. The most commonly used biomarkers 
of PAH exposure are DNA and protein 
adducts measured in blood; however, it is also 
possible to measure parent PAHs in blood 
and their hydroxy metabolites in urine. Some 
studies have used DNA or protein adducts that 
are specific to BaP (e.g., BaP diol epoxide–
DNA or protein adducts), whereas others use 
nonspecific “bulky DNA adducts” or “BaP-
like adducts” detected by 32-P–post labeling 
and immunoassays (Boysen and Hecht 2003; 
Käfferlein et al. 2010). Additional methods 
development is needed because researchers 
have had limited success differentiating 
between exposed and unexposed populations 
through the use of BaP-specific adducts, and it 
is unclear how measurements of PAH adducts 
or specific PAH concentrations relate either to 
specific exposures or to the overall carcinogenic 
potency of the complex mixture of PAHs in 
the environment (Shantakumar et al. 2005).
Perfluorooctanoic acid (PFOA). PFOA 
and other perfluorinated compounds (PFCs) 
are used in non  stick and stain-resistant 
coatings on rugs, furniture, clothes, and 
cookware as well as in fire-fighting applica-
tions, cosmetics, lubricants, paints, and 
adhesives. They are widely detected in blood 
samples in the United States (Lau et al. 2007). 
Despite the many consumer uses of this exten-
sive and complex class of surfactant chemicals, 
the most important sources of exposure and 
health effects are not well defined. Exposure 
via use of consumer products is likely impor-
tant, and in addition these compounds are 
common drinking-water and food contami-
nants (D’Hollander et al. 2010). PFOA has 
shown weak evidence of mammary tumors 
in rodents and has also been shown to 
disrupt estrogen, thyroid, and peroxisome 
proliferator–activated receptor (PPAR)– 
mediated hormonal signaling, as well as to 
alter mammary gland development (Lau et al. 
2007; White et al. 2011). PFCs are persis-
tent and are readily measured in blood in the 
general U.S. population as well as in groups 
exposed occupationally or through industrial 
contamination. NHANES has measured 
several PFCs, including PFOA, and reported 
detectable levels in the majority of the general 
population (Alwis et al. 2012).
Non hormonal  pharmaceuticals. A 
number of pharmaceuticals that are not 
prescribed as hormonally active drugs have 
been shown to cause rodent mammary 
tumors (Rudel et al. 2007). These include 
four chemotherapeutic agents, two veterinary 
drugs possibly present in food (2-amino-
5-nitrothiazole and nitrofurantoin), the 
diuretic furosemide, the anti  fungal griseo-
fulvin, several anti  infective agents, and two 
drugs that are no longer widely used (phenac-
etin, an over-the-counter pain reliever and the 
anti  hypertensive drug reserpine) (Rudel et al. 
2007). Few exposure biomarkers can detect 
low-level exposures in the general population, 
but many studies have used LC-MS/MS to 
measure parent compounds in plasma, or 
metabolites in urine, to describe pharmaco-
kinetics, monitor patients, and, in the case of 
at least one chemotherapeutic agent, monitor 
exposure of health care workers. In some 
cases, exposure can be ascertained from self-
report or medical records (see Supplemental 
Material, Table S1).
Styrene. Exposure to styrene in the general 
population occurs at levels of micrograms per 
day due mainly to inhalation of indoor air 
and cigarette smoke and intake of food that 
has been in contact with polystyrene. Styrene 
is present in consumer products and building 
materials, including polystyrene, carpets, 
adhesives, hobby and craft supplies, and home 
maintenance products (IARC 2002; NTP 
2011). NHANES and others have measured 
styrene and its metabolites and adducts in 
blood samples from the general population 
(Blount et al. 2006). Urinary mercapturic and 
mandelic acid metabolites will be included 
in future NHANES assessments (Alwis et al. 
2012). A few studies have measured styrene 
in human saliva and breast milk (Blount et al. 
2010; Sanchez et al. 2012).
Other chemicals. Twenty-seven addi-
tional high-exposure mammary gland 
carcinogens do not fall into the 17 priority 
categories described above but are still priori-
ties for exposure and epidemiological studies 
(see Supplemental Material, Table S1). 
Exposure sources and biomarker methods 
for these are summarized in Supplemental 
Material, Table S1, along with methods 
for the chemicals in the groups described 
above. The 27 additional chemicals (see 
Supplemental Material, Table S1) include 
some pesticides, some chemicals that may be 
present in consumer products (e.g., acrylo-
nitrile, nitrobenzene, dyes), and some food-
related chemicals. For example, urethane is 
an industrial chemical but also a product of 
fermentation, methyl eugenol is a natural 
and artificial flavoring, and nitrosamines have 
been reported in some smoked meats but can 
also have industrial uses. Pesticides include 
captafol, clonitralid, 1,2-dibromochloro-
propane, dichlorvos, fenvalerate, malachite 
green, and sulfallate. Pesticides were not 
included as a group in Table 2 because they 
are not chemically similar and therefore 
require different methods for exposure 
measurement. About half of these pesticides 
have had some type of exposure biomarker 
method reported in the literature (e.g., 
Coronado et al. 2011; Riederer et al. 2008).
Animal–human concordance. Results 
of human breast cancer studies are generally 
consistent with rodent bioassays, although few 
agents have been studied in humans. There is 
consistent evidence in humans and animals 
for associations between breast cancer risk and 
hormonal pharmaceuticals, ionizing radiation, 
light at night/shift work, alcoholic beverages, 
EtO, heterocyclic amines/grilled meat, PAHs/
tobacco smoke, and common industrial 
solvents (Brody et al. 2007a; Cogliano et al. 
2011; Michels et al. 2007; Rudel et al. 2007). 
A single study by Kaiser Permanente evaluated 
breast cancer among women prescribed five 
non  hormonal pharma  ceuticals that have been 
shown to cause rodent mammary tumors and 
found small but significantly increased risk for 
three of these, but no increased risk for two 
others (Friedman et al. 2009).
Table 3 also shows that animal and 
human evidence is consistently negative for 
some agents that do not induce mammary 
tumors in standard cancer bioassays. Studies 
of persistent organochlorine chemicals like 
dichlorodiphenyltrichloroethane (DDT), 
polychlorinated biphenyls (PCBs), and 
dioxin—which act as EDCs rather than as 
classical carcinogens—also show consistent 
findings between animal and human studies. 
These chemicals do not increase mammary 
gland tumors in standard cancer bioassays, 
which expose adult animals; similarly, human 
studies have generally not found significant 
relationships between adult serum concen-
trations and breast cancer risk. However, 
these EDCs may increase risk with early-life 
exposure by altering mammary gland develop-
ment or hormone responsiveness, and there 
is limited evidence for this from both human 
and animal studies (Brody and Rudel 2008; 
Cohn et al. 2007; Rudel et al. 2011). Studies 
of genetically homogeneous animals have not 
evaluated the genetic differences in suscepti-
bility that were suggested by human studies on 
PCBs and breast cancer (Brody et al. 2007b).
Breast cancer cohorts with archived biolog-
ical samples. We identified opportunities to 
apply novel exposure measures in breast cancer 
epidemiology in the form of 60 cohort studies 
and tissue banks that have collected biological 
samples from female participants years before 
ascertaining breast cancer incidence, breast 
cancer recurrence, or pubertal timing (see 
Supplemental Material, Tables S2 and S3).
The majority of these [42 studies, with 
a total of about 3.5 million enrolled women 
(see Supplemental Material, Table S2)] have 
ascertained or will ascertain breast cancer 
incidence as an outcome measure; one of Rudel et al.
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these 42 studies also collected information on 
pubertal outcomes for the women’s daugh-
ters. An additional three studies, with a total 
of approximately 5,500 women enrolled, 
collected samples from women after a primary 
breast cancer diagnosis and are prospectively 
studying survival, recurrence, and contra-
lateral primary breast cancer. A few of these 
studies have already included measurements 
of environmental chemicals (most commonly 
organochlorine pesticides) in blood, although 
many have so far used biological samples 
primarily to assess hormone levels and poly-
morphisms. The study populations, despite 
being mostly North American and western 
European, represent a wide variety of ethnic 
and demographic groups.
In addition, we identified 15 more 
cohort studies, with > 70,000 enrolled 
girls and young women (see Supplemental 
Material, Table S3), that collected biological 
samples and measured or will measure age 
at menarche, breast development, hormones, 
and other indicators of pubertal timing and 
reproductive health. Many of these studies 
have collected samples from their participants 
during infancy and from the girls’ mothers 
during pregnancy. Two of these have infor-
mation on menopausal or other maternal 
outcomes. Assessing biomarkers of exposure 
to EDCs and other chemicals in these studies 
could provide valuable information about 
links between these chemicals and changes 
in breast development and pubertal timing. 
Given the importance of pubertal develop-
ment to later-life breast health, and the 
well-established connection between early 
menarche and breast cancer risk, informa-
tion about these end points could provide 
insights into the mechanisms by which early-
life   environmental exposures alter breast 
cancer risk.
Supplemental Material, Table S2, also 
includes 10 studies that, to our knowledge, 
have not collected biological samples from 
their participants but nonetheless provide 
opportunities for prospectively studying 
  environmental exposures and breast cancer.
Discussion
We compiled biomonitoring methods for 102 
chemicals that are high priorities for breast 
cancer research and prevention efforts. We 
systematically identified these chemicals 
based on evidence that they cause mammary 
tumors in rodent bioassays and on produc-
tion and use information that suggests current 
or historical exposure to the general popu-
lation. We condensed the priority list into 
17 chemical groups for immediate attention. 
Il’yasova et al. (2009) recently published a 
similar approach for expanding the scope of 
brain tumor epidemiology by prioritizing 
animal neurocarcinogens.
Our results show ample opportunity to 
expand breast cancer epidemiology beyond 
the small number of chemicals studied to date. 
Exposure biomarkers have been developed for 
> 70 chemicals that caused mammary tumors 
in rodent studies. These biomarkers can be 
studied in several existing breast cancer cohort 
studies that have both biological samples 
and extensive information on potentially 
confounding breast cancer risk factors. The 
exposure biomarkers also can be included in 
biomonitoring programs in order to identify 
highly exposed groups for further study and 
to guide and track exposure reduction. In 
addition, we identified some knowledge gaps 
in existing measurements that point to areas 
for future methods development.
The application of exposure biomarkers 
for mammary carcinogens requires thoughtful 
consideration of study design issues (see 
below). The first two parts of this discussion 
address interpretation of exposure biomarkers 
within the exposure-to-disease continuum 
articulated by Perera and Weinstein (2000). 
In this framework, exposure biomarkers (e.g., 
markers of internal dose) and early effect 
markers (e.g., DNA adducts) are considered 
intermediate points that can be related back 
to exposure and forward to disease (Perera and 
Weinstein 2000). First, we discuss strengths 
and weaknesses of selecting these chemicals for 
study based on animal evidence of their poten-
tial relationships with human disease. Second, 
we describe types of exposure biomarkers 
and factors that influence relationships 
with exposure sources. Within each of these 
discussions, we present new research related to 
novel analyses that move beyond a “one-chem-
ical-at-a-time” approach to consider multiple 
exposures. Third, we identify the highest 
priority biomarkers and key study design 
strate  gies for breast cancer epidemiology. 
Fourth, we discuss using exposure biomarkers 
as tools for breast cancer prevention.
Relationships between exposure biomarkers 
and disease. In this review, we prioritized 
chemicals to measure in breast cancer studies 
Table 3. Comparison of human and animal evidence for agents identified as plausibly linked to breast cancer in major reviews.a
Agent Human breast Rodent mammary Reference (human) Reference (rodent)
Estrogenic pharmaceuticals
HRT (estrogen–progestin) Positive Positive Cogliano et al. 2011 Rudel et al. 2007
HRT (estrogen only) Limited positiveb Positive Cogliano et al. 2011 Rudel et al. 2007
Estrogen–progestin contraceptives Positive Positive Cogliano et al. 2011 Rudel et al. 2007
DES (mother and daughter) Positive Positive Cogliano et al. 2011; Hoover et al. 2011 Rudel et al. 2007
Other pharmaceuticals
Griseofulvin, furosamide, metronidazole Limited positiveb Positive Friedman et al. 2009 Rudel et al. 2007
Indomethacin, nitrofurantoin Limited null findingc Positive Friedman et al. 2009 Rudel et al. 2007
Miscellaneous
Ionizing radiation Positive Positive Cogliano et al. 2011 Rudel et al. 2007
Ethanol/drinking alcoholic beverages Positive Limited positiveb Cogliano et al. 2011 Oyesanmi et al. 2010
Heterocyclic amines in grilled/fried meat Limited positiveb Positive Michels et al. 2007 Rudel et al. 2007
Light at night/shift work/circadian Limited positiveb Positive Cogliano et al. 2011 Stevens 2009
EtO Limited positiveb Positive Cogliano et al. 2011 Rudel et al. 2007
PAHs (auto exhaust, cigarette smoke) Limited positiveb Positive Cogliano et al. 2011 Rudel et al. 2007
Common industrial solvents Limited positiveb Positive Brody et al. 2007a Rudel et al. 2007
Persistent organochlorines
DDE [(DDT metabolite) in older adult blood) Null Null Brody et al. 2007a; Snedeker 2001 NTP 1978
DDT (in blood at young age) Limited positiveb No study Brody et al. 2007a;.Cohn et al. 2007 —
PCBs (in older adult blood) Null Null Brody et al. 2007a NTP 2011
PCBs (in subpopulations with polymorphism) Limited positiveb No relevant model Brody et al. 2007a —
TCDD/dioxin (in early life) Limited positiveb Positive (with carcinogen challenge) Brody et al. 2007a; Warner et al. 2011 Brown et al. 1998
Abbreviations: DDE, dichlorodiphenyldichloroethylene; TCDD, 2,3,7,8 tetrachlorodibenzo-p-dioxin.
aAgents with strongest human breast cancer evidence from reviews by IARC (2012b), Cogliano et al. (2011), Brody et al. (2007a), Hoover et al. (2011), Michels et al. (2007) and Friedman 
et al. (2009). Animal study findings from original research papers, NTP reports, and other government reports. bFollowing Cogliano et al. (2011), “limited positive” indicates evidence 
sufficient to establish a credible causal relationship but not sufficient to rule out chance, bias, or confounding. cA single study (Friedman et al. 2009) found no association between 
these two pharmaceuticals and breast cancer.Exposure biomarkers for breast cancer epidemiology
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based on toxicology and laboratory data. 
Before investing in the biomarkers we iden-
tified, researchers will want to consider the 
evidence that they are relevant to humans, 
so we discuss that evidence here. Laboratory 
evidence suggests at least three overlapping 
classes of chemicals that might increase breast 
cancer risk: a) chemicals that cause mammary 
gland tumors in animal cancer bioassays, 
primarily by damaging DNA, b) EDCs that 
accelerate the growth of mammary tumors 
through estrogenic or other pathways, and 
c) developmental toxicants that can alter devel-
opment of the mammary gland in ways that 
permanently increase susceptibility (Brody 
and Rudel 2008). Many ubiquitous environ-
mental pollutants common in workplaces, 
consumer products, and building materials fall 
into one or more of these categories (Brody 
2010; Rudel et al. 2007, 2011). Although 
these classes provide a framework for identi-
fying chemicals of interest, they are based on 
simplified descriptions of complex biological 
pathways. For example, although chemicals 
might disrupt mammary gland development 
or promote breast tumor formation or growth 
through estrogenic or genotoxic activity, these 
effects could also arise from other disruptions 
in the tissue microenvironment or in cell–
cell communications (Boudreau et al. 2012; 
Sonnenschein and Soto 2013).
Relevance of animal carcinogens to human 
risk. Animal models of chemically induced 
cancer are the primary means of understanding 
and anticipating the effects of chemicals in 
humans. For pharmaceutical agents, animal 
studies guide development before human 
clinical trials can occur. For commercial chemi-
cals and pollutants, particularly when human 
data are not available, they guide prevention 
strategies to reduce environmentally associated 
cancers by reducing exposures (Huff 1996; 
Rall 2000). The cancer bioassay is designed 
to identify genotoxic carcinogens. Although 
some chemicals induce positive responses in 
this test through non  genotoxic mechanisms, 
different tests are needed to identify carcino-
gens that act by promoting growth of existing 
tumors, by altering tissue structure during 
development (Birnbaum and Fenton 2003), 
by otherwise altering the tissue microenviron-
ment (Boudreau et al. 2012), by disrupting 
cell–cell communication (Sonnenschein and 
Soto 2013), or by transgenerational epigen-
etic phenomena (Ruden et al. 2005). Gaps in 
knowledge about biological pathways that are 
important in breast development and carcino-
genesis limit our ability to anticipate which 
chemicals may increase risk and to identify the 
developmental stages with the greatest suscepti-
bility to chemical exposures.
The use of animal studies to identify 
human carcinogens is supported by observa-
tions about the overall concordance of human 
studies with animal tests. All known human 
carcinogens that have been adequately tested 
in animals are also carcinogenic in animal 
models and have at least one common organ 
site in both humans and the animal model 
(Huff 1993, 1999; Huff and Melnick 2006). 
Historically, about one-third of known human 
carcinogens were shown to be carcinogenic 
in animals before being confirmed as carcino-
gens in epidemiological studies, which means 
human cancers could have been prevented had 
exposures been reduced on the basis of animal 
evidence (Huff and Melnick 2006; IARC 
2006). Based on these and other findings, 
IARC has concluded that “it is biologically 
plausible that agents for which there is suffi-
cient evidence of carcinogenicity in experi-
mental animals also present a carcinogenic 
hazard to humans…” and “in the absence of 
additional scientific information, these agents 
are considered to pose a carcinogenic hazard to 
humans” (Cogliano et al. 2011; IARC 2006).
Narrower inferences—that a chemical 
is not just carcinogenic, but carcinogenic in 
a specific target organ—can be more tenta-
tive because target organs for carcinogens are 
not necessarily the same across species. Thus, 
although it is likely that chemicals that cause 
mammary tumors in rats will also cause 
tumors in some organs in mice and humans, 
the mammary gland may not necessarily 
be the target in humans (Gold et al. 1991; 
Haseman and Huff 1987). Characterizing the 
relevance of various rodent models specifically 
to human breast cancer is still an area of active 
research (Rudel et al. 2007, 2011); however, at 
present, these rodent cancer bioassays provide 
the strongest evidence of potential breast 
cancer risk factors. In fact, Table 3 shows 
that there is substantial agreement between 
studies of human breast cancer and of rat 
mammary tumors for agents that have been 
studied in both.
However, not all rodent mammary carcino-
gens are equally carcinogenic. The chemicals 
vary in the strength of evidence that they are 
likely to be human carcinogens, and each 
must be evalua  ted with respect to potency, 
dose response, target sites, tumor incidence 
and multiplicity, anticipated induction period, 
and exposure routes and levels in humans. In 
general, most rodent mammary carcinogens 
also show evidence of genotoxicity and tumors 
at other target sites, and these observations 
support the inference that they would also be 
carcinogenic in humans (Rudel et al. 2007). 
However, some mammary carcinogens (e.g., 
chlordane) induce inconsistent responses in 
animals, whereas others (e.g., atrazine) induce 
tumors through mechanisms that reliable 
biological information suggests are not likely to 
be rele  vant in humans (Rudel et al. 2007).
Considering the toxicologic data, it 
is somewhat puzzling that studies of breast 
cancer risk associated with tobacco smoking 
have not been more consistently positive 
because many tobacco smoke constituents 
are mammary gland carcinogens, and specific 
mutations associated with these carcino-
gens are found at higher concentrations in 
breast tumors from smokers compared with 
non  smokers (Conway et al. 2002). Several 
major reviews have concluded that exposure to 
tobacco smoke is associated with higher breast 
cancer risk (Collishaw et al. 2009; IARC 
2012; IOM 2011; Reynolds 2013), but these 
conclusions have been controversial because 
many studies have not seen an association 
(reviewed by Palmer and Rosenberg 1993). 
In general, breast cancer risk shows the stron-
gest associations with exposure during early 
life while breast tissue is less differentiated. 
Using “unexposed” groups that exclude 
non  smokers with passive smoke exposure also 
strengthens the observed associations (Lash 
and Aschengrau 1999; Reynolds 2013). In 
addition, researchers have hypothesized that 
the inconsistent and weak findings may be due 
to the competing effect of the anti  estrogenic 
activity of tobacco smoke constituents, which 
would be expected to reduce breast cancer 
risk (Lash and Aschengrau 1999; MacMahon 
et al. 1982; Xue et al. 2011). This hypothe  sis 
is supported by numerous studies that report 
unchanged or decreased breast cancer risk in 
current or recent smokers because the anti-
estrogenic effects should be strongest near 
diagnosis. Furthermore, recent results from 
the Women’s Health Initiative showed a 
positive association between smoking and 
postmenopausal breast cancer only among 
non-obese women (Luo et al. 2011). The 
authors speculated that the anti  estrogenic 
effects of smoking counteract the effects of 
the estrogen produced by adipose in obese 
postmenopausal women.
Although we highlight the agents that 
have been most thoroughly evaluated in 
humans, more comprehensive reviews of the 
epidemiological literature on environmental 
chemicals and breast cancer are available 
elsewhere (Brody et al. 2007a; IBCERCC 
2013; IOM 2011).
EDCs as potential breast carcinogens. 
One limitation of our focus on mammary 
carcinogens is that traditional rodent cancer 
bioassays may not be sensitive to the effects of 
EDCs because these studies only dose adult 
animals, do not evaluate altered susceptibility 
or tumor promotion, and terminate the 
studies while the animals are still fairly young, 
equivalent to about 65 years of age in humans 
(Huff et al. 2008; Rudel et al. 2011). Some 
endogenous and pharmaceutical hormones, 
such as estrogen, progesterone, and diethyl-
stilbestrol, are associated with increased 
breast cancer risk in humans and in rodents 
(Cogliano et al. 2011; Hoover et al. 2011), and Rudel et al.
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these observations have raised concerns that 
EDCs, including common consumer product 
chemicals that are weak estrogens or have other 
hormonal activity, could contribute to breast 
cancer risk (Brody and Rudel 2008; Dodson 
et al. 2012; Rudel et al. 2003). Although most 
commercial chemicals have not been screened 
for endocrine disruption, we identified 22 
rodent mammary gland carcinogens that are 
also EDCs, including amsonic acid, PFOA, 
and chlordane.
Mixtures. Another limitation is our focus 
on measures of individual chemicals. A priority 
for future research is to develop biomarkers 
that integrate the effects of multi  ple exposures 
on the same biological pathway and that detect 
early effects of chemical exposure. Rather than 
measuring the level of an individual chemical, 
these methods can integrate effects of multiple 
agents and do not depend on a priori knowl-
edge of each potentially relevant chemical. For 
example, some studies have sought to measure 
total exposure to exogenous estrogenic chemi-
cals in adipose by using a functional in vitro 
assay for estrogenic activity (Fernandez et al. 
2007; Rasmussen et al. 2003), and others have 
proposed a method to measure protein adducts 
formed by all reactive electrophiles (Rappaport 
et al. 2012) or measures of oxidative stress and 
DNA damage (e.g., Arlt and Schwerdtle 2011).
Similarly, environment-wide associa-
tion studies (EWAS) adapt the strategies of 
discovery-  based genome-wide association 
studies (GWAS) to identify environmental 
chemical exposures linked to disease. For 
example, Patel et al. (2010, 2013) used 
NHANES to conduct an EWAS study looking 
across all measured exposures for associations 
with diabetes. Because there are so many 
chemical exposures, and it is impossible to 
measure each one and anticipate its relation-
ship with disease, these discovery-based tech-
niques are an important tool for generating 
new hypotheses that can be tested in health 
studies (Rappaport 2011, 2012).
Relationships between biomarkers and 
exposure. In addition to understanding how 
biomarkers relate to disease, it is crucial to 
understand their relationship to exposure 
sources. Efforts to identify highly exposed 
populations, develop relevant epidemio-
logical study designs, and reduce exposures 
all benefit from a deep understanding of the 
relationship between biomarkers and exposure 
sources. These relationships are influenced by 
pharmacokinetics that dictate the chemicals’ 
absorption, distribution, metabolism, and 
excretion (ADME). These ADME parame  ters, 
taken together with knowledge of exposure 
pathways, also provide insight into the relative 
advantages of using biological versus environ-
mental measures for a particular application. A 
good understanding of ADME is essential for 
selecting useful biomarkers and interpreting 
biomarker measurements, and some key 
considerations are discussed below.
Types of exposure biomarkers: parent, 
metabolite, reactant/adduct. Exposure to some 
of the chemicals reviewed here can be assessed 
by measuring the parent compound. In other 
cases, especially when the parent compound is 
quickly metabolized or otherwise difficult to 
measure, a metabolite or a DNA or protein 
adduct may be preferable. Because DNA 
adducts are considered to represent an initial 
stage in a carcinogenic process, DNA adducts 
can provide information about biological 
effects as well as exposure (Izzotti et al. 1999).
For some exposures, the chemical most 
easily measured as a biomarker is not the 
biologically active moiety, and this can lead 
to exposure misclassification. For example, 
many epidemiological studies have used serum 
dichlorodiphenyldichloroethylene (DDE) 
levels as a proxy for exposure to DDT (Brody 
and Rudel 2008). However, serum DDE levels 
measured decades after DDT was banned 
largely reflect exposure to DDE via the food 
chain and not exposure to the more-active 
DDT (Snedeker 2001). The DNA-reactive 
metabolites of many genotoxic compounds 
are very short lived in the blood and so cannot 
be reliably measured; in such cases, longer-
lasting protein or DNA adducts with the active 
metabolite often prove more informative. For 
carcinogenic PAHs, such as BaP, methods to 
measure the specific genotoxic metabolite inde-
pendently or as a protein adduct are not sensi-
tive enough for use in the general population, 
and common, less-specific ELISA methods 
do not reliably differentiate between exposed 
and unexposed people (Käfferlein et al. 2010). 
Urinary metabolites are often used in prefer-
ence to the parent compound in blood because 
urine collection is less invasive; however, differ-
ences in urine metabolite levels can represent 
individual differences in metabolic capability 
in addition to differences in exposure, again 
leading to exposure misclassification if the 
biomarker is not the biologically active agent.
Some exposure biomarkers are common 
metabolites of multiple parent compounds. 
This can be an advantage in a health study 
if all the possible parent compounds are 
believed to act additively and with potency 
proportional to metabolite levels, but it can 
be a disadvantage if this is not the case or if 
the study is trying to characterize exposure to 
a single parent compound. For example, in 
NHANES, CDC measurements of HEMA 
in urine reflect possible exposure to several 
hazardous chemicals, including vinyl chloride, 
EtO, and ethylene dibromide (Calafat et al. 
1999). Variation in HEMA levels can be asso-
ciated with variation in exposure to any of the 
possible parent compounds.
For chemicals that are excreted rapidly, 
it can be difficult to find biomarkers that 
reflect a longer-term exposure, especially 
when exposures are episodic. For example, for 
chemicals with short biological half-lives, such 
as bisphenol A (BPA), urine concentrations 
from one person can vary over the course of 
a single day because exposure occurs at meals 
and the compound is rapidly metabolized and 
excreted (Teeguarden et al. 2011). This daily 
variation is so great that a single spot urine 
BPA level may not differentiate longer-term 
exposure among a group of people. Exposure 
biomarkers would ideally be biologically 
persistent enough that concentrations in 
the biological matrix are detectable and will 
reflect average exposure rather than time since 
exposure. Combining multiple spot samples is 
another way to estimate average exposure to 
rapidly metabolized chemicals. In other cases, 
a protein- or DNA-bound metabolite, or an 
effect marker such as DNA mutation in blood 
lymphocytes, may be long-lived and represent 
previous exposure after the parent compound 
or metabolite can no longer be detected 
(Manjanatha et al. 1996). For example, the 
hemoglobin adduct for EtO represents cumu-
lative exposure over several months, whereas 
the urinary metabolite HEMA is short-lived 
and non  specific (Alwis et al. 2012; Ogawa 
et al. 2006).
Although blood and urine concentra-
tions are generally considered good proxies 
for internal dose at the target tissue, factors 
that can influence these relationships should 
be considered. For example, estradiol concen-
trations in blood and adipose tissue are not 
always well correlated (Falk et al. 2012). 
Similarly, studies of chemically induced 
DNA adducts and DNA damage in blood 
and mammary tissue have shown that blood 
samples are not always representative of levels 
in mammary tissue (Delclos et al. 1996; 
Izzotti et al. 1999; Manjanatha et al. 1996).
Blood and urine samples are the most 
common matrices for exposure monitoring, 
but methods are available to measure some 
biomarkers in other matrices such as exhaled 
breath and breast milk. Breast milk is a 
valuable medium for exposure monitoring 
because it can be collected noninvasively at 
substantial volume, the high fat content 
captures lipophilic compounds, and it reflects 
exposures to young women and infants. Other 
matrices that can be used for biomonitoring 
include fine-needle aspirates of breast ductal 
fluid (Mills et al. 2011), hair (e.g., Bessette 
et al. 2009), adipose tissue (e.g., Covaci et al. 
2002; Dewailly et al. 1999; Falk et al. 2012), 
saliva (e.g., Bessette et al. 2010), exhaled breath 
(e.g., Cope et al. 2004; Plebani et al. 1999), 
and fingernails (Esteban and Castaño 2009).
Biological versus environmental measures. 
In epidemiological studies, biological exposure 
measures are often preferred to environmental 
measures such as chemical concentration in Exposure biomarkers for breast cancer epidemiology
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drinking water or house dust. In some cases, 
however, there are advantages to using envi-
ronmental measures instead or in addition. 
Biological exposure measures are powerful 
when they can assess the biologically active 
component (parent or metabolite) in blood or 
at the target tissue and during the appropriate 
exposure window. Exposure misclassification 
commonly results from uses of biomarkers that 
do not fulfill these criteria, which can include 
measuring a component (parent or metabo-
lite) that is not the active moiety (e.g., DDE 
rather than DDT), measuring in urine rather 
than blood (questionable proxy for circu-
lating levels given inter  individual differences 
in metabolism and excretion), and measuring 
after the critical exposure window. In some 
cases, chemical measurements in exposure 
media (e.g., drinking water, air, house dust) 
may provide a reliable estimate of intake. For 
example, systematically collected data can 
facilitate the estimation of contaminant levels 
in the tap water serving large numbers of study 
participants (Legay et al. 2011). Similarly, 
measurements of chemicals in house or other 
indoor dust may be representative of long-term 
exposure from indoor environments given that 
pollutants degrade slowly in dust, keeping 
concentrations in dust relatively constant 
over time (Quirós-Alcalá et al. 2011). People 
spend most of their time indoors (U.S. EPA 
2011a), making air and dust in indoor envi-
ronments important sources of exposure to 
many chemicals used in consumer products 
and building materials that have been linked 
to health effects, including cancer. Thus, in 
some studies it may be useful to collect envi-
ronmental samples, such as house dust or air, 
in addition to biological samples.
Research needs. Chemical-specific 
pharmaco  kinetic studies, often performed in 
animals, are important tools for identifying 
the best exposure biomarkers and under-
standing relationships between exposures and 
biomarkers. For example, many researchers 
used monoethylhexylphthalate as a primary 
biomarker for diethylhexyl phthalate (DEHP) 
exposure until ADME studies indicated that 
it was a minor metabolite (6%) compared 
with oxidized DEHP metabolites, which 
represent 70% of excreted DEHP and are 
longer lived (Koch et al. 2006).
New “omics”-based chemical analytical 
approaches to exposure assessment offer the 
opportunity to discover important exposure 
biomarkers without having to know a priori 
what chemical or metabolite to target 
(Rappaport 2011, 2012). For example, 
metabo  lomics techniques, widely used to 
investigate pharmaceuticals’ effects on levels 
of small molecules in blood, have been used 
to identify exposure biomarkers (Park et al. 
2012). These exposome approaches are 
an especially promising tool for identifying 
exposure biomarkers for complex mixtures 
such as vehicle exhaust. Proteomic tech-
niques can also identify adducts as exposure 
biomarkers.
Many health studies rely on a limited 
number of available retrospective exposure 
measures, very few of which provide informa-
tion about in utero exposures. One promising 
technique involves measuring chemicals in 
baby teeth, in which it appears chemicals are 
deposited and retained in utero and during 
early childhood (Camann et al. 2012). 
Additional development and validation of this 
approach could permit a wide range of chemi-
cals to be detected and exposure assigned to 
particular developmental periods based on 
when particular tooth areas are formed.
Exposure biomarkers in breast cancer 
epidemiology. Given that the best-established 
risk factors for breast cancer are associated 
with fairly modest increases in risk (e.g., odds 
ratios < 2), it is likely that to be sensitive to 
the effects of environmental chemicals, breast 
cancer epidemiology will require thoughtful 
design informed by mechanistic evidence, 
and many kinds of exposures may ultimately 
not be suitable for study in humans. One of 
the most promising opportunities for finding 
associations is to study exposures to genotoxic 
carcinogens in younger women (< 50 years of 
age at diagnosis) with high exposures, and with 
follow-up of at least 10–20 years. Cohorts with 
occupational exposures, for example, may have 
elevations in risk high enough to be detected in 
epidemiological studies.
For exposures that do lend themselves 
to epidemiological study, careful choice of 
biomarkers is essential to capturing the rele
vant exposures, and in many cases improved 
biomarkers are needed. Many genotoxic 
rodent mammary carcinogens are metabolized 
rapidly, necessitating either repeated measure-
ments or measurements of protein or DNA 
adducts to reflect exposure over an extended 
period. Studies of hormone disruption would 
be strengthened by integrated measures for 
hormonal activity to augment measurements 
of individual chemicals, an approach currently 
hampered by lack of knowledge about what 
chemicals might affect a given pathway and 
to what degree. Finally, measures to estimate 
in utero exposures retrospectively among 
women diagnosed in their 40s–60s could lead 
to more informative studies of this important 
life stage.
Epidemiological studies must also consider 
a number of challenging design problems 
beyond selecting appropriate exposure 
measures. Because multiple factors influence 
breast cancer risk (including many factors that 
are potentially confounding because they are 
correlated with demographics that also are 
related to environmental exposures), building 
on cohort studies that have already collected 
information on established risk factors is 
helpful. Empirical induction periods between 
exposure and breast cancer diagnosis range 
from > 50 years for in utero exposure to 
hormones (Hoover et al. 2011) to 10–20 years 
for classical genotoxic agents to < 5 years 
for hormone exposure later in life (IOM 
2011), creating implications for the length 
of follow-up needed for studies of environ-
mental   chemicals that operate by different 
mechanisms.
Study designs matched to more sophisti-
cated biological hypotheses will likely prove 
more informative than studies that do not 
take into account current understanding of 
the complexities of breast cancer. Effects of 
a particular agent may be limited to specific 
sub  diseases within the hetero  geneous outcome 
called “breast cancer.” For example, an analysis 
of 34 studies found that reproductive factors 
and body mass index (BMI) are only associ-
ated with hormone-receptor-positive tumors 
and not with basal type (triple negative) 
tumors (Yang et al. 2011). Other effects 
appear stronger in subgroups with particular 
risk factors, as evident in the repeated observa-
tions that body size has a stronger effect on the 
risk of breast cancer among post  menopausal 
women, and that the association with alcohol 
intake is stronger among women with certain 
polymorphisms in enzymes responsible for 
alcohol metabolism (IOM 2011). An addi-
tional example of effect modification is that 
breast tissue is more sensitive to ionizing 
radiation before the differentiation that occurs 
during a woman’s first full term pregnancy 
(Henderson et al. 2010; Land 1995).
Studies of other outcomes related to breast 
cancer incidence might avoid some of the diffi-
culties inherent in studies of primary breast 
cancer incidence. Recurrence and hormonal 
status of breast cancers, as well as ability to 
lactate, likely respond to more recent exposures 
and provide information specific to individual 
biological pathways and breast cancer types. 
Assessments of puberty in girls, including age 
at menarche, hormonal status, and Tanner 
breast development staging, provide some 
information about the effects on early-life 
mammary gland development, which may 
have a profound impact on breast cancer risk 
later in life (Rudel et al. 2011). More sophis-
ticated measures of breast development, if 
identified, would improve researchers’ ability 
to extrapolate from effects of early-life exposure 
to later breast cancer risk.
Epidemiological studies that are consid-
ering using archived biological samples to 
measure exposures must also carefully consider 
the validity of any new measurements. For 
example, researchers should evaluate both 
the stability of the analyte under the relevant 
sample collection and storage procedures 
as well as the possibility of background Rudel et al.
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contamination from sampling apparatus or 
containers. Important considerations have 
been highlighted by Rothman et al. (1995), 
the Nurses’ Health Study (2014), and Calafat 
et al. (2013).
Exposure biomarkers as tools for breast 
cancer prevention. In light of the difficulties 
inherent in using environmental epidemiology 
to study cancer risk factors, a recent IARC 
review of human carcinogens concluded that 
“every Group 1 agent can be considered to 
represent cancers that might have been 
prevented had scientists been able to predict 
cancer hazards earlier or had public health 
authorities been willing to act more quickly 
when scientific information became available” 
(Cogliano et al. 2011; IARC 2012). This 
report and others (IBCERCC 2013; IOM 
2011; President’s Cancer Panel 2010) all 
support efforts to use and improve predictive 
toxicology methods (animal, in vitro, in silico) 
to enable smarter decisions limiting exposures 
based on biologically plausible effects on 
breast cancer risk.
Biomonitoring data are becoming criti-
cally important in risk-based prioritization 
exercises that direct exposure control and 
additional research (Bevan et al. 2012; Rudel 
and Perovich 2012). Once toxicity testing 
indicates approximate doses associated with 
biological effects, comparison with biomoni-
toring data can help focus on exposures of 
greatest concern. Based on this extensive 
review, the chemicals listed in Table 2 and 
in Supplemental Material, Table S1, are 
important priorities for biomonitoring of both 
the general population and highly exposed 
subpopulations such as occupationally exposed 
groups. The identification of highly exposed 
women and men can focus exposure reduc-
tion and epidemiological studies on exposures 
likely to be associated with breast cancer.
By characterizing distributions of expo-
sures in the population, biomonitoring can 
also provide information on the public health 
impact of exposure and potential benefits of 
exposure reduction. For example, Bellinger 
(2012) used blood lead levels to demonstrate 
that lead exposure in childhood is responsible 
for almost as great an impact on the intel-
ligence quotient (IQ), on a population level, 
as is preterm birth. This dramatic effect arises 
because although the individual effect on IQ 
from low-level exposure is small, exposure is 
widespread. Similarly, widespread exposure to 
chemicals plausibly linked with breast cancer 
could be responsible for many preventable 
breast cancers.
Estimates of breast cancer risk attribut-
able to well-established risk factors such as 
HRT, alcohol, physical inactivity, reproduc-
tive history, and family history of breast cancer 
can provide some context for considering 
the potential benefits of reducing chemical 
exposure. One model estimated that by 
optimizing BMI, alcohol consumption, and 
physical activity, the 20-year absolute breast 
cancer risk for an average 45-year-old in a 
population of Italian women would be reduced 
from 6.5% to 5.1%, with larger reductions 
among women with more risk factors (Petracci 
et al. 2011). Population attributable risk (PAR) 
estimates, which provide a sense of the relative 
difference in breast cancer risk between the 
whole population and the unexposed portion 
of the population, vary widely across studies 
of established risk factors, including alcohol 
(2–11%), HRT (4–27%), and physical inac-
tivity (6–20%) (IOM 2011). A German study 
estimated a breast cancer PAR for a combi-
nation of less-modifiable risk factors (age at 
menarche/menopause, parity, benign breast 
disease, family breast cancer history) at 37% 
(Barnes et al. 2011).
Estimating PARs for rodent mammary 
carcinogens is difficult because of the lack of 
evidence regarding both the strength of the 
association between exposure and disease and 
the prevalence of the exposures. Although 
few rodent mammary carcinogens have been 
studied in humans—and the studies have 
methodo  logical weaknesses—increased odds 
range from 30% to 400%, which is within the 
range observed for the established risk factors 
(Brody et al. 2007a; Cohn et al. 2007). The 
opportunity for breast cancer prevention by 
reducing exposure to chemicals such as the 
rodent mammary carcinogens is significant 
because animal evidence suggests that some 
are potent carcinogens, widespread exposures 
to many have been established, and popula-
tions highly exposed to others may be iden-
tified in future surveillance. Furthermore, 
because public and industrial policies drive 
exposure to many rodent mammary carcino-
gens, exposure information is needed to 
inform public health decision making.
Conclusions
This review substantially broadens directions 
for studying chemicals and breast cancer by 
compiling biomarker measurement tech-
niques for 102 plausible breast carcinogens 
and prioritizing 17 chemical groups for study, 
biomonitoring, and exposure reduction. These 
priorities include components of automobile 
exhaust, gasoline, and air pollution (1,3-buta-
diene, benzene, PAHs, nitro-PAHs), chemi-
cals in food and drinking water (acrylamide, 
ochratoxin A, heterocyclic amines, styrene, 
MX), chemicals in consumer products and 
building materials (flame retardants, aromatic 
amines, PFCs), pharmaceuticals, EDCs, and 
some chemicals with important occupational 
exposures (halogenated solvents, EtO).
We found that exposure measurement 
methods are available for almost three-  quarters 
of the 102 rodent mammary gland carcinogens 
evaluated, and some analytes could be assessed 
using existing methods for related chemicals. 
Methods have been published for 73 of the 
102 chemicals. Exposure biomarkers for 62 
have been measured in humans, and 45 were 
measured in a non  occupationally exposed 
population, including 23 measured by the 
CDC in the general U.S. population. In some 
cases, analytical methods for biological samples 
permit the measurement of many analytes in 
a single sample. Epidemiological studies of 
breast cancer risk are generally consistent with 
rodent bioassays, although only a few agents 
have been studied in humans. We identified 
42 cohort studies with a total of > 3.5 million 
enrolled women that have ascertained breast 
cancer incidence as an outcome measure and 
have collected biological samples, presenting 
numerous opportunities to apply novel 
exposure measures in breast cancer epidemi-
ology. Biomonitoring programs following the 
priorities we have laid out could effectively 
assess exposure and identify highly exposed 
groups, enabling the development of strategies 
to prevent breast cancer by reducing exposure 
to plausible breast carcinogens.
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